You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFr

Showing 26 - 50 of 5,630
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

Recruiting
  • Brain Metastases
  • +2 more
  • Guangdong, Guangzhou, China
    Sun-Yat-Sen university
Mar 13, 2023

NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)

Not yet recruiting
  • NSCLC
  • Idylla EGFR_IUO/3.20 Mutation Test
  • (no location specified)
Jul 24, 2023

NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Befotertinib + Icotinib placebo
  • Icotinib + Befotertinib placebo
  • Beijing, China
  • +2 more
Sep 20, 2023

Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Lung Cancer Stage IV
  • EGFR T790M
  • Seoul, MA, Korea, Republic of
    Samsung Medical Center
Jan 26, 2023

NSCLC Trial (Almonertinib Envafolimab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Almonertinib Envafolimab
  • (no location specified)
Sep 10, 2022

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

NSCLC Trial in Guangzhou (Neratinib tablets)

Not yet recruiting
  • NSCLC
  • Neratinib tablets
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 1, 2023

Adenocarcinoma of the Stomach Trial in Goyang (Anti-EGFR antibody in combination with weekly paclitaxel)

Recruiting
  • Adenocarcinoma of the Stomach
  • Anti-EGFR antibody in combination with weekly paclitaxel
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Nov 29, 2022

A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +4 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Oct 25, 2022

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    HLX07, nsqNSCLC, High EGFR Expression Trial in Shanghai (HLX07+carboplatin+pemetrexed, HLX07+docetaxel, HLX07)

    Not yet recruiting
    • HLX07, nsqNSCLC, High EGFR Expression
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 5, 2022

    Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR

    Completed
    • Metastatic Colorectal Adenocarcinoma
      • (no location specified)
      Oct 9, 2023

      Lung Cancer Trial in Guangzhou (Aumolertinib)

      Not yet recruiting
      • Lung Cancer
      • Guangzhou, Guangdong, China
        The First Affiliated Hospital of Guangzhou Medical University
      Jul 7, 2023

      Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

      Recruiting
      • Bronchial Neoplasms
      • Cologne, Germany
      • +6 more
      Nov 2, 2022

      Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Aug 31, 2023

      NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

      Recruiting
      • Non-small Cell Lung Cancer
      • SH-1028 tablets
      • Placebo SH-1028 tablets
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Oct 6, 2023

      NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

      Not yet recruiting
      • NSCLC
      • Oral S-1 + Oral Osimertinib
      • Singapore, Singapore
        National Cancer Center Singapore
      Mar 6, 2023

      EGFR Mutation-Related Tumors Trial (NX-019)

      Not yet recruiting
      • EGFR Mutation-Related Tumors
      • (no location specified)
      Aug 22, 2022

      Small-cell Lung Cancer Trial in Guangzhou (Serplulimab)

      Recruiting
      • Small-cell Lung Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial Perople's Hospital
      Jul 20, 2023

      NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • HS-10241+ Almonertinib
      • Pemetrexed + Cisplatin /Carboplatin
      • (no location specified)
      Oct 29, 2023

      NSCLC Trial in Omaha (PLB1004)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Omaha, Nebraska
        Nebraska Cancer Specialists
      Sep 19, 2023

      EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

      Recruiting
      • EGFR Exon 20 Mutation
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 12, 2022

      Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

      Not yet recruiting
      • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
      • +6 more
        • (no location specified)
        Aug 9, 2022